In vivo effects of tepoxalin, an inhibitor of cyclooxygenase and lipoxygenase, on prostanoid and leukotriene production in dogs with chronic osteoarthritis
Authors:
- Lisa R. ReynoldsLRLisa R. Reynolds
- Steven C. BudsbergSBSteven C. Budsberg
- 1 June 2005
- journal article
- research article
- Published by American Veterinary Medical Association (AVMA) in American Journal of Veterinary Research
- Vol. 66 (6) , 966-972
Abstract
Objective—To evaluate in vivo effects of tepoxalin, an inhibitor of cyclooxygenase (COX) and lipoxygenase (LOX), on prostaglandin (PG) and leukotriene production in osteoarthritic dogs. Animals—7 mixed-breed adult dogs with chronic unilateral arthritis of a stifle joint. Procedure—Dogs were treated in accordance with a randomized 3-way crossover design. Each dog received an inert substance, meloxicam, or tepoxalin for 10 days. On day 0 (baseline), 3, and 10, dogs were anesthetized and samples of blood, stifle joint synovial fluid, and gastric mucosa were collected. Concentrations of PGE2 were measured in synovial fluid and after lipopolysaccharide stimulation of whole blood; PGE1 and PGE2 synthesis was measured in gastric mucosa. Thromboxane B2 (TxB2) concentration was measured in whole blood. Leukotriene B4 (LTB4) concentration was determined in gastric mucosa and in whole blood after ex vivo stimulation with a calcium ionophore. Results—Tepoxalin significantly decreased LTB4 concentrations in the blood and gastric mucosa at day 10 and TxB2 concentrations in the blood and PGE2 in the gastric mucosa and synovial fluid at days 3 and 10, compared with baseline values. Meloxicam significantly decreased PGE2 concentrations in the blood at days 3 and 10 and synovial fluid at day 3. Meloxicam also decreased PGE1 and PGE2 synthesis in the gastric mucosa at day 3. Meloxicam did not affect LTB4 synthesis in the blood or LTB4 concentrations in the gastric mucosa. Conclusions and Clinical Relevance—Tepoxalin has in vivo inhibitory activity against COX-1, COX-2, and 5-LOX in dogs at the current approved recommended dosage. (Am J Vet Res 2005;66:966–972)Keywords
This publication has 35 references indexed in Scilit:
- Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical useBritish Journal of Clinical Pharmacology, 2002
- Dual acting anti-inflammatory drugs: a reappraisalPharmacological Research, 2001
- A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymesTrends in Pharmacological Sciences, 1997
- Gastroduodenal mucosal defenseCurrent Opinion in Gastroenterology, 1996
- Leukotrienes do not contribute to the pathogenesis of indomethacin-induced ulceration of the gastric antrum in the re-fed ratInflammation Research, 1994
- Role of Leukotrienes in Indomethacin-Induced Mucosal Damage in RatsJournal of Clinical Gastroenterology, 1993
- Leukotrienes in the pathogenesis of NSAID-induced gastric and intestinal mucosal damageInflammation Research, 1993
- Leukotriene B4 level in stimulated blood neutrophils and alveolar macrophages from healthy and asthmatic subjects. Effect of beta-2 agonist therapyEuropean Journal of Clinical Investigation, 1992
- Vascular injury in acute gastric mucosal damageDigestive Diseases and Sciences, 1988
- Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytesNature, 1980